Clinical efficacy of vorinostat in a patient with leiomyosarcoma

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 101-105

  Lee, Jin ^a   McGuire, Colin ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Histone deacetylase inhibitor; Leiomyosarcoma; Lung metastases; Soft tissue sarcoma; Vorinostat

Indexed keywords

ALPHA ACTIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; MESNA; MYOSIN HEAVY CHAIN; PACLITAXEL; PROTEIN S 100; VIMENTIN; VORINOSTAT;

ADULT; ARTICLE; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; METABOLIC PARAMETERS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCYTOPENIA; PATIENT PREFERENCE; SIDE EFFECT; TREATMENT OUTCOME; TUMOR BIOPSY; UTERUS TUMOR;

EID: 84863032900     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S7194     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. van Vliet M, Kliffen M, Krestin GP, et al. Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. Eur Radiol 2009;19:1499-511.
3. McMillian Cancer support group: treating soft tissue sarcomas, 09 update. http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Softtissuesarcomas/Treatingsofttissuesarcomas/Treatingsofttissuesarcomas.aspx Accessed November 19, 2009.
4. Brennan MF, Singer S, Maki RG, et al. Sarcomas of the soft tissue and bone, in DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology, 8th ed. Philadelphia, PA, USA: Lippincott-Raven; 2008:1741-94.
5. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25: 2755-63.
6. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987;5:840-50.
7. Palumbo R, Palmeri S, Antimi M, et al. Phase II study of continuousinfusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol. 1997;8:1159-62.
8. Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer. 2006;95(Suppl 1):S2-6.
9. Mann BS, Johnson JR, Sridhara R, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007;13:2318-22.
10. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923-31.
11. Olsen EA, Kim Y-H, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-15.
12. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31-9.
13. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060-6.
14. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166-73.
15. Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49:502-7.
16. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19:964-9.
17. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res. 2009;15:5250-7.
18. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006;7:257-61.
19. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008;26:81-7.
20. Luu TH, Morgan RJ, Leong L, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a california cancer consortium study. Clin Cancer Res. 2008;14:7138-42.
21. Traynor AM, Dubey S, Eickhoff JC, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a wisconsin oncology network phase II study. J Thorac Oncol. 2009;4:522-6.
22. Vansteenkiste J, Van CE, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008;26:483-8.
23. Modesitt SC, Sill M, Hoffman JS, et al. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2008; 109:182-6.
24. Duvic M, Olsen EA, Breneman D, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-Cell lymphoma (CTCL). Clin Lymphoma Myeloma (in press).
25. Skubitz KM, Skubitz AP. Differential gene expression in leiomyosarcoma. Cancer. 2003;98:1029-38.
26. Trzyna W, McHugh M, McCue P, et al. Molecular determination of the malignant potential of smooth muscle neoplasms. Cancer. 1997;80:211-7.
27. Miyajima K, Tamiya S, Oda Y, et al. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction. Cancer Lett. 2001;164: 177-88.
28. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74:659-71.
29. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007;76:75-100.
30. Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, et al. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol. 2008;10:395-8.
31. Nguyen A, Su L, Campbell B, et al. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma. 2009:794-901.
32. Ecke I, Petry F, Rosenberger A, et al. Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009;69:887-95.
33. Hurtubise A, Bernstein ML, Momparler RL. Preclinical evaluation of the antineoplastic action of 5-aza-2′-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int. 2008;8:16.
34. Yamamoto S, Tanaka K, Sakimura R, et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res. 2008;28:1585-91.
35. Lubieniecka JM, de Bruijn DR, Su L, et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res. 2008;68: 4303-10.
36. Hrzenjak A, Kremser ML, Strohmeier B, et al. SAHA induces caspaseindependent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol. 2008;216:495-504.
37. Sakimura R, Tanaka K, Yamamoto S, et al. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res. 2007;13:275-82.
38. Navid F, Mischen BT, Helman LJ. Low dose histone deacetylase inhibitor, depsipeptide (FR901228), promotes adenoviral transduction in human rhabdomyosarcoma cell lines. Sarcoma. 2004;8:25-30.
39. Lopez G, Liu J, Ren W, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res. 2009;15:3472-83.